Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Mohamed Ghonim Stories

2014-01-10 16:21:55

DUBLIN, January 10, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/j635wj/nephrology_and) has announced the addition of the "2013 Report on the International Nephrology and Urology Devices Market - Industry Analysis, Size, Share, Trends and Forecast to 2018" [http://www.researchandmarkets.com/research/j635wj/nephrology_and ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )...

2013-10-30 10:01:27

Enterocystoplasty is a good surgical option with a low rate of severe complications in the treatment of children who were born with developmental abnormalities of the genitourinary system, according to the new study conducted by a group of Portuguese urologists. Enterocystoplasty is a surgical enlargement of the urinary bladder which is performed to improve bladder function as a low-pressure reservoir. "This issue is very important because in children this surgical procedure is very...

2013-10-08 13:46:09

New ACS NSQIP® study identifies low blood albumin level as an independent risk factor for surgical-related health problems after radical cystectomy Patients with bladder cancer are two times more likely to have complications after a radical cystectomy procedure if they have a biomarker for poor nutritional status before the operation, according to study findings presented today at the 2013 Clinical Congress of the American College of Surgeons. Surgeons from the University of North...

2013-08-07 08:29:41

WINSTON-SALEM, N.C., Aug. 7, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced the promotion of A. Brian Davis to Chief Financial Officer and Senior Vice President, Finance. Mr. Davis has served as Chief Financial Officer of Tengion since joining the Company in 2010 and recently helped facilitate the Company in raising $33.6M to fund research and development activities for its two lead clinical programs, the Neo-Kidney Augment(TM) and...

2013-07-08 16:26:49

BELLEVILLE, ON, July 8, 2013 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced the outcome of a meeting in late June with Health Canada, at which time the Company discussed the filing of a regulatory submission for its Phase III bladder cancer product - Urocidin(TM) - under Health Canada's Notice of Compliance with Conditions (NOC/c) policy. Health Canada advised the Company...

2012-12-21 20:20:43

-Bioniche identifies potential for early access to the Canadian market- BELLEVILLE, ON, Dec. 21, 2012 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that global rights to Urocidin(TM) are being returned to the Company from Endo Pharmaceuticals (Endo), a subsidiary of Endo Health Solutions. On November 5(th), it was announced that a second Phase III clinical trial with...

2012-12-19 15:09:08

Patients with muscle invasive bladder cancer may experience less loss of blood and shorter hospital stays as a result of robotic-assisted surgery, new randomized study in the Journal of Urology About 30 percent of the more than 70,000 bladder cancer cases expected in 2012 are muscle invasive. In such cases, radical cystectomy is the preferred treatment. In a pilot trial, a team of investigators assessed the efficacy of open radical cystectomy (ORC) vs. robotic-assisted laparoscopic radical...

2012-11-19 16:29:28

BALTIMORE, Nov. 19, 2012 /PRNewswire/ -- For the second consecutive year, four urologists from Chesapeake Urology Associates, PA have been named to the Super Doctors® 2012 List for the Maryland/Washington, D.C., area. These physicians are among just five percent in the region to be honored with inclusion on the Super Doctors 2012 List. Each year, Key Professional Media undertakes a rigorous multi-phase selection process that includes a survey of doctors, independent evaluation of...

2012-11-16 08:23:11

BALTIMORE, Nov. 16, 2012 /PRNewswire/ -- Chesapeake Urology Associates, PA is pleased to announce that six of its urologists and two of its radiation oncologists have been selected by their peers as 2012 Top Doctors in Baltimore magazine. Nearly 10,000 physicians in the region were surveyed to find out where they would send a member of their own family in dozens of specialties, including urology and radiation oncology. "We are proud of all of our physicians who work tirelessly to provide...

2012-10-26 07:23:31

WINSTON-SALEM, N.C., Oct. 26, 2012 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that two patients in the Phase 1 clinical trial of the Company's most advanced product candidate, the Neo-Urinary Conduit(TM), have recently died due to afflictions unrelated to the Neo-Urinary Conduit or the surgical procedure. The fourth patient enrolled in the trial died of metastatic bladder cancer, which had not responded to combination chemotherapy and...